For research use only. Not for therapeutic Use.
Tenofovir alafenamide fumarate (Cat No.:I003393) serves as the prodrug of Tenofovir, which is an HIV-1 nucleotide reverse transcriptase inhibitor. Tenofovir alafenamide fumarate is designed to be more efficiently absorbed and converted into its active form, Tenofovir diphosphate, within cells. As a potent inhibitor of HIV-1 reverse transcriptase, Tenofovir diphosphate impedes viral replication by preventing the synthesis of viral DNA. This antiviral medication is commonly used as part of combination therapy to effectively manage HIV-1 infection and prevent the progression of AIDS.
| Catalog Number | I003393 |
| CAS Number | 379270-38-9 |
| Synonyms | (S)-isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate fumarate |
| Molecular Formula | C25H33N6O9P |
| Purity | ≥95% |
| Target | HIV |
| Solubility | DMSO: ≥ 42 mg/mL |
| Storage | 2-8°C |
| IUPAC Name | (E)-but-2-enedioic acid;propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate |
| InChI | InChI=1S/C21H29N6O5P.C4H4O4/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;2-1+/t15-,16+,33+;/m1./s1 |
| InChIKey | MEJAFWXKUKMUIR-FHPNUNMMSA-N |
| SMILES | CC(C)OC(=O)C(C)NP(=O)(COC(C)CN1C=NC2=C(N=CN=C21)N)OC3=CC=CC=C3.C(=CC(=O)O)C(=O)O |
| Reference | <p style=/line-height:25px/> <br>[1]. Babusis D, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013 Feb 4;10(2):459-66. <br>[2]. Ruane PJ, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. |
